Laurus Labs Q2 Net Profit More Than Doubles To ₹441 Crore; To Acquire Stakes In Galenvs Science And SI&C Resins

New Delhi, October 29, 2026 - Pharma and biotech company Laurus Labs announced a significant surge in its net profit for the second quarter, more than doubling to ₹441 crore. This marked a substantial improvement from ₹195 crore in the same period last year. The company's growth was primarily attributed to its Contract Development and Manufacturing Organisation (CDMO) and affordable medicine segments.

Laurus Labs announced intentions to bolster its market position by acquiring stakes in two Canadian companies. The firm entered into a definitive agreement to acquire a 60% stake in Galenvs Science, a company specializing in oligonucleotides and precision magnetic nanoparticles. This acquisition aims to expand Laurus Labs' presence in the rapidly growing oligonucleotide market.

Additionally, the company agreed to acquire a 52% stake in SI&C Resins, a firm focused on peptide-resin technology. This move enhances Laurus Labs' supply chain security and strengthens its competitiveness in peptide manufacturing by incorporating peptide solid support resins and chromatography stationary phases.

Satyanarayana Chava, the Founder and Chief Executive Officer of Laurus Labs, shared details of the company's strategic advancements. He mentioned that Laurus Labs had operationalized its first commercial-scale peptide plant in Vizag using advanced operating systems. Furthermore, the company is currently in the process of a significant capacity expansion to meet the surging demand for peptide therapeutics.

Laurus Labs also highlighted targeted investments in oligonucleotides and peptide-resin technologies, which bolstered its integrated CDMO offering.

Revenue increased by 33% year-on-year during the July-September period, reaching ₹2,206 crore. This growth was seen in both the CDMO and Affordable Medicine divisions. Executives reported a 78% increase in EBITDA to ₹762 crore, with margins at 34.5%, driven by improved capacity efficiency from expanding commercial supplies.